This is a single-centre, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment Phase 1 study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of HL40626S tablets following single and multiple ascending oral doses to healthy adult participants aged 18-55 years.
Official registry: https://clinicaltrials.gov/study/NCT07736586 · HighsLab Therapeutics Inc. · enrollment listed as 64
Phase 1: the first tests in people. The main question is safety and dose, not whether it cures the condition. Groups are small. Side effects are watched closely.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
If you join, the listed intervention(s) are HL40626S tablets, or HL40626S placebo. The registry lists allocation as randomized. This is a single-centre, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment Phase 1 study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of HL40626S tablets following single and multiple ascending oral doses to healthy adult participants aged 18-55 years.
They plan to enroll about 64 people at 2 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
A Randomized, Double-Blind, Placebo-Controlled, Sequential Group, 2-Part, Phase Ι Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HL40626S Tablets Following Oral Administration of Single and Multiple Ascending Doses to Healthy Adult Participants.
Interventions: HL40626S tablets, HL40626S placebo
Primary outcome (registry wording): Parts 1 (SAD) and 2 (MAD): Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Arockiaa P Aarthy Joseph, MBBS
a.joseph@nucleusnetwork.com.au
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g.
NCT01848028 · Official ClinicalTrials.gov record · Universitätsklinikum Hamburg-Eppendorf
Glucocorticoids remain to be among the most important and most frequently used anti-inflammatory and immunosuppressive or immune-modulatory acting drugs to treat rheumatic (and other) diseases. Unfortunately, glucocorticoids also exert undesired effects, especially if higher dosages have to be given over longer periods of time.
NCT02719314 · Official ClinicalTrials.gov record · Prof Dr Frank Buttgereit
The purpose of this pediatric study is to measure the drug levels, how well it works and safety of Deucravacitinib in children and adolescent participants aged 4 to \<18 years with moderate to severe plaque psoriasis. This study includes two cohorts; Cohort 1 (age 12 to \<18 years) and Cohort 2 (age 4 to \<12 years), with two parts; for each cohort.
NCT04772079 · Official ClinicalTrials.gov record · Bristol-Myers Squibb
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Phase 1. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary